在之前接受BCMA向治疗后,多发性骨髓瘤患者接受ide-cel的现实世界经验
Christopher J Ferreri1, Michelle A T Hildebrandt1, Hamza Hashmi2
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Blood cancer journal
|August 9, 2023
概括
患有复发性多发性骨髓瘤的患者接受了顺序的B细胞成熟抗原向治疗 (BCMA-TT),其反应率较低,无进展存活时间较短,与idecabtagene vicleucel. 然而,之前接受CAR T细胞治疗的患者获得了最好的结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 多发性髓瘤在B细胞成熟抗原向治疗 (BCMA-TT) 后经常复发.
- 有限的数据存在于顺序BCMA-TT治疗后的结果.
- 伊德-卡巴特基因维克卢塞尔 (ide-cel) 是一种标准的抗BCMA仿真抗原受体 (CAR) T细胞疗法.
研究的目的:
- 为了评估前期BCMA-TT暴露和没有BCMA-TT暴露的患者中ide-cel的实际临床结果.
- 为了比较这两个患者队列之间的安全性和有效性.
主要方法:
- 对50名曾经接触过BCMA-TT的患者和153名没有BCMA-TT的患者进行了回顾性分析.
- 患者在11个美国医疗中心接受了标准护理.
- 之前的BCMA-TT队列的随访持续时间为4.5个月,之前没有BCMA-TT队列的6.0个月.
主要成果:
- 两个队列之间的安全结果是可比的.
- 之前的BCMA-TT队列表现出较低的整体应答率 (74% vs 88%),更短的中位数应答持续时间 (7.4 vs 9.6 个月) 和较低的中位数无进展生存期 (3.2 vs 9.0 个月).
- 所有五名先前接受了抗BCMA CAR T细胞治疗的患者都对ide-cel有反应,在这个小组中显示出最好的生存结果.
结论:
- 在之前用BCMA-TT治疗的患者中,Ide-cel提供了临床反应.
- 与以前没有BCMA-TT暴露的患者相比,响应率和持续时间低于最佳.
- 序列BCMA-TT,特别是CAR T细胞疗法,需要进一步研究,以优化多发性骨髓瘤治疗.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.9K
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.4K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
557
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
557
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
